Publisher Correction: COVID-19 vaccine BNT162b1 elicits human antibody and T_H1 T cell responses

Nature. 2021 Feb;590(7844):E17. doi: 10.1038/s41586-020-03102-w.

Authors

Ugur Sahin^{1

2}, Alexander Muik³, Evelyna Derhovanessian³, Isabel Vogler³, Lena M Kranz³, Mathias Vormehr³, Alina Baum⁴, Kristen Pascal⁴, Jasmin Quandt³, Daniel Maurus³, Sebastian Brachtendorf³, Verena Lörks³, Julian Sikorski³, Rolf Hilker³, Dirk Becker³, Ann-Kathrin Eller³, Jan Grützner³, Carsten Boesler³, Corinna Rosenbaum³, Marie-Cristine Kühnle³, Ulrich Luxemburger³, Alexandra Kemmer-Brück³, David Langer³, Martin Bexon⁵, Stefanie Bolte³, Katalin Karikó³, Tania Palanche³, Boris Fischer³, Armin Schultz⁶, Pei-Yong Shi⁷, Camila Fontes-Garfias⁷, John L Perez⁸, Kena A Swanson⁸, Jakob Loschko⁸, Ingrid L Scully⁸, Mark Cutler⁸, Warren Kalina⁸, Christos A Kyratsous⁴, David Cooper⁸, Philip R Dormitzer⁸, Kathrin U Jansen⁸, Özlem Türeci³

Affiliations

¹ BioNTech, Mainz, Germany. ugur.sahin@biontech.de.
² TRON gGmbH-Translational Oncology at the University Medical Center of the Johannes Gutenberg, Mainz, Germany. ugur.sahin@biontech.de.
³ BioNTech, Mainz, Germany.
⁴ Regeneron Pharmaceuticals, Tarrytown, NY, USA.
⁵ Bexon Clinical Consulting, Upper Montclair, NJ, USA.
⁶ CRS Clinical Research Services Mannheim GmbH, Mannheim, Germany.
⁷ University of Texas Medical Branch, Galveston, TX, USA.
⁸ Pfizer, Pearl River, NY, USA.

PMID: 33469214
DOI: 10.1038/s41586-020-03102-w

No abstract available

Publication types

Published Erratum